x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
¨ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
27-4079982 | |
(STATE OF INCORPORATION) | (I.R.S Employer I.D.) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Common Stock, par value $0.0001 per share | CTM | NYSE American LLC |
Accelerated filer ¨ | |||
Non-accelerated filer x | Smaller reporting company x | ||
Emerging growth company x |
Class | Outstanding as of November 10 , 2022 |
Common Stock, par value $0.0001 per share | 41,539,342 |
· |
changes in the market acceptance of our products and services; |
· |
overall levels of government spending, including defense spending and spending on IT services; |
· |
increased levels of competition; |
· |
changes in political, economic, or regulatory conditions generally and in the markets in which we operate; |
· |
adverse conditions in the industries in which our customers operate; |
· |
our ability to retain and attract senior management and other employees; |
1 |
· |
our ability to respond quickly and effectively to new technological developments; |
· |
our ability to protect our trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on the proprietary rights of the Company; |
· |
United States government imposes sequestration in the absence of an approved budget or continuing resolution; |
· |
existing revenues related to small business are not replaced by other opportunities; |
· |
our Company fails to win prime contracts or acquire companies with prime contract vehicles; and |
· |
other risks, including those described in “Part II, Item 1A. Risk Factors” discussion of this Quarterly Report on Form 10-Q. |
|
· |
We lack a long-term operating history on which to evaluate our consolidated business and determine if we will be able to execute our business plan, and we can give no assurance that our operations will result in sustained profitability; |
|
· |
We have historically suffered net losses and we may not be able to sustain profitability; |
|
· |
We rely upon a few, select key employees who are instrumental to our ability to conduct and grow our business. In the event any of those key employees would no longer be affiliated with the Company, and we did not replace them with equally capable replacements, it may have a material detrimental impact as to our ability to successfully operate our business; |
|
· |
We generate substantially all of our revenue from contracts with the United States Federal, state, and local governments which are subject to a number of challenges and risks that may adversely impact our business, prospects, financial condition, and operating results; |
|
· |
We operate in an industry that is highly regulated and unexpected changes to laws could have a significant adverse impact on our business; |
2 |
|
· |
Our business could be adversely affected by changes in spending levels or budgetary priorities of the United States Federal, state, and local governments or by the imposition by the United States government of sequestration in the absence of an approved budget or continuing resolution; |
|
· |
We face intense competition and could fail to gain market share from our competitors, which could adversely affect our business, financial condition, and results of operations; |
|
· |
We may have difficulty identifying and executing acquisitions on favorable terms and therefore may grow slower than we historically have grown; and |
|
· |
We may have difficulty raising additional capital, which could deprive us of necessary resources, and you may experience dilution or subordinate stockholder rights, preferences, and privileges as a result of our financing efforts. |
3 |
4 |
THREE MONTHS ENDED | NINE MONTHS ENDED | |||||||||||||||
SEPTEMBER 30, | SEPTEMBER 30, | |||||||||||||||
2022 | 2021 | 2022 | 2021 | |||||||||||||
REVENUES | $ | 11,120,712 | $ | 7,378,094 | $ | 32,166,104 | $ | 15,587,246 | ||||||||
COST OF REVENUES | 6,474,261 | 4,309,439 | 18,698,820 | 8,921,153 | ||||||||||||
GROSS PROFIT | 4,646,451 | 3,068,655 | 13,467,284 | 6,666,093 | ||||||||||||
OPERATING EXPENSES | ||||||||||||||||
Indirect costs | 2,130,513 | 738,239 | 7,458,319 | 1,512,370 | ||||||||||||
Overhead | 407,804 | 248,540 | 1,167,346 | 431,987 | ||||||||||||
General and administrative expenses | 3,297,319 | 6,682,034 | 9,633,064 | 10,389,922 | ||||||||||||
Loss from change in fair value of contingent earnout | 864,000 | - | 864,000 | - | ||||||||||||
Total operating expenses | 6,699,636 | 7,668,813 | 19,122,729 | 12,334,279 | ||||||||||||
LOSS FROM OPERATIONS BEFORE OTHER INCOME (EXPENSE) | (2,053,185 | ) | (4,600,158 | ) | (5,655,445 | ) | (5,668,186 | ) | ||||||||
OTHER INCOME (EXPENSE) | ||||||||||||||||
Realized gain on investment | - | - | - | 38,851 | ||||||||||||
Gain on disposal of fixed assets | - | - | 303 | - | ||||||||||||
Change in fair value of derivative liability | 76,000 | - | (97,000 | ) | - | |||||||||||
Interest expense, net of interest income | (978,314 | ) | (648,175 | ) | (2,579,915 | ) | (1,838,032 | ) | ||||||||
Total other income (expense) | (902,314 | ) | (648,175 | ) | (2,676,612 | ) | (1,799,181 | ) | ||||||||
LOSS FROM OPERATIONS BEFORE BENEFIT | ||||||||||||||||
FOR INCOME TAXES | (2,995,499 | ) | (5,248,333 | ) | (8,332,057 | ) | (7,467,367 | ) | ||||||||
INCOME TAX (EXPENSE) BENEFIT | (159,025 | ) | 328,735 | (902,820 | ) | 890,995 | ||||||||||
NET LOSS | (3,114,524 | ) | (4,919,598 | ) | (9,234,877 | ) | (6,576,372 | ) | ||||||||
Less: Preferred Stock Dividends | 29,911 | 3,320 | 70,447 | 3,320 | ||||||||||||
NET LOSS TO COMMON SHAREHOLDERS | $ | (3,144,435 | ) | $ | (4,922,918 | ) | $ | (9,305,324 | ) | $ | (6,579,692 | ) | ||||
NET LOSS PER SHARE - BASIC AND DILUTED | $ | (0.12 | ) | $ | (0.26 | ) | $ | (0.39 | ) | $ | (0.38 | ) | ||||
WEIGHTED AVERAGE SHARES OUTSTANDING - BASIC AND DILUTED | 25,868,849 | 18,679,462 | 23,621,551 | 17,414,469 |
5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional |
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
|
Series A Preferred |
|
|
Series B Preferred |
|
|
Series C Preferred |
|
|
Common Stock |
|
|
Paid-In |
|
|
Subscription |
|
|
Accumulated |
|
|
|
|
||||||||||||||||||||||||
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
Capital |
|
|
Receivable |
|
|
Deficit |
|
|
Total |
|
||||||||||||
Balance - December 31, 2020 |
|
|
5,875,000 |
|
|
$ |
588 |
|
|
|
3,610,000 |
|
|
$ |
361 |
|
|
|
- |
|
|
$ |
- |
|
|
|
15,411,264 |
|
|
$ |
1,541 |
|
|
$ |
6,133,332 |
|
|
$ |
- |
|
|
$ |
(3,527,296 |
) |
|
$ |
2,608,526 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock-based compensation - options |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
263,610 |
|
|
|
- |
|
|
|
- |
|
|
|
263,610 |
|
Stock-based compensation - warrants |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
188,186 |
|
|
|
- |
|
|
|
- |
|
|
|
188,186 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss for the period |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(829,532 |
) |
|
|
(829,532 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance - March 31, 2021 |
|
|
5,875,000 |
|
|
|
588 |
|
|
|
3,610,000 |
|
|
|
361 |
|
|
|
- |
|
|
|
- |
|
|
|
15,411,264 |
|
|
|
1,541 |
|
|
|
6,585,128 |
|
|
|
- |
|
|
|
(4,356,828 |
) |
|
|
2,230,790 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares issued in acquisition of MFSI |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
1,114,023 |
|
|
|
111 |
|
|
|
1,782,326 |
|
|
|
- |
|
|
|
- |
|
|
|
1,782,437 |
|
Cancellation of shares in acquisition of MFSI |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(250,000 |
) |
|
|
(25 |
) |
|
|
(399,975 |
) |
|
|
- |
|
|
|
- |
|
|
|
(400,000 |
) |
Stock-based compensation - options |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
407,271 |
|
|
|
- |
|
|
|
- |
|
|
|
407,271 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss for the period |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(827,242 |
) |
|
|
(827,242 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance - June 30, 2021 |
|
|
5,875,000 |
|
|
|
588 |
|
|
|
3,610,000 |
|
|
|
361 |
|
|
|
- |
|
|
|
- |
|
|
|
16,275,287 |
|
|
|
1,627 |
|
|
|
8,374,750 |
|
|
|
- |
|
|
|
(5,184,070 |
) |
|
|
3,193,256 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares issued in acquisition of Merrison |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
500,000 |
|
|
|
50 |
|
|
|
1,699,950 |
|
|
|
- |
|
|
|
- |
|
|
|
1,700,000 |
|
Shares issued in acquisition of SSI, net of transaction costs |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
2,600,000 |
|
|
|
260 |
|
|
|
5,149,240 |
|
|
|
- |
|
|
|
- |
|
|
|
5,149,500 |
|
Shares issued for cash in Series C Preferred Subscription Agreements |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
520,000 |
|
|
|
52 |
|
|
|
52,000 |
|
|
|
5 |
|
|
|
519,943 |
|
|
|
(100,000 |
) |
|
|
- |
|
|
|
420,000 |
|
Stock-based compensation - options |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
1,600,217 |
|
|
|
- |
|
|
|
- |
|
|
|
1,600,217 |
|
Stock-based compensation - warrants |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
2,846,416 |
|
|
|
- |
|
|
|
- |
|
|
|
2,846,416 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss for the period |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(4,922,918 |
) |
|
|
(4,922,918 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance - September 30, 2021 |
|
|
5,875,000 |
|
|
$ |
588 |
|
|
|
3,610,000 |
|
|
$ |
361 |
|
|
|
520,000 |
|
|
$ |
52 |
|
|
|
19,427,287 |
|
|
$ |
1,942 |
|
|
$ |
20,190,516 |
|
|
$ |
(100,000 |
) |
|
$ |
(10,106,988 |
) |
|
$ |
9,986,471 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance - December 31, 2021 |
|
|
5,875,000 |
|
|
$ |
588 |
|
|
|
3,610,000 |
|
|
$ |
361 |
|
|
|
620,000 |
|
|
$ |
62 |
|
|
|
19,960,632 |
|
|
$ |
1,996 |
|
|
$ |
26,405,126 |
|
|
$ |
- |
|
|
$ |
(11,086,016 |
) |
|
$ |
15,322,117 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock-based compensation - options |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
875,640 |
|
|
|
- |
|
|
|
- |
|
|
|
875,640 |
|
Stock-based compensation - warrants |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
Stock-based compensation - restricted shares |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
30,937 |
|
|
|
- |
|
|
|
- |
|
|
|
30,937 |
|
Shares issued in acquisition of MFSI |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
Cancellation of shares in acquisition of MFSI |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
Shares issued for service, net of amounts prepaid |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
7,500 |
|
|
|
1 |
|
|
|
6,187 |
|
|
|
- |
|
|
|
- |
|
|
|
6,188 |
|
Shares issued in exercise of stock options |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
15,000 |
|
|
|
2 |
|
|
|
11,998 |
|
|
|
- |
|
|
|
- |
|
|
|
12,000 |
|
Shares issued for cash in Series C Preferred |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Subscription Agreement |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
150,000 |
|
|
|
15 |
|
|
|
15,000 |
|
|
|
2 |
|
|
|
149,983 |
|
|
|
- |
|
|
|
- |
|
|
|
150,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss for the period |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(1,406,715 |
) |
|
|
(1,406,715 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance - March 31, 2022 |
|
|
5,875,000 |
|
|
|
588 |
|
|
|
3,610,000 |
|
|
|
361 |
|
|
|
770,000 |
|
|
|
77 |
|
|
|
19,998,132 |
|
|
|
2,001 |
|
|
|
27,479,871 |
|
|
|
- |
|
|
|
(12,492,731 |
) |
|
|
14,990,167 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares issued for services, net of amounts prepaid |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
7,500 |
|
|
|
1 |
|
|
|
11,939 |
|
|
|
- |
|
|
|
- |
|
|
|
11,940 |
|
Shares issued for cash, including fair value adjustment |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
1,250,000 |
|
|
|
125 |
|
|
|
592,875 |
|
|
|
- |
|
|
|
- |
|
|
|
593,000 |
|
Shares issued for commitment fees |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
125,000 |
|
|
|
12 |
|
|
|
59,288 |
|
|
|
- |
|
|
|
- |
|
|
|
59,300 |
|
Shares issued to satisfy obligation to issue common stock |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
132,500 |
|
|
|
13 |
|
|
|
533,737 |
|
|
|
- |
|
|
|
- |
|
|
|
533,750 |
|
Shares issued to acquire LSG |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
600,000 |
|
|
|
60 |
|
|
|
2,279,940 |
|
|
|
- |
|
|
|
- |
|
|
|
2,280,000 |
|
Common shares issued in conversion of Series B Preferred Stock |
|
|
- |
|
|
|
- |
|
|
|
(535,000 |
) |
|
|
(54 |
) |
|
|
- |
|
|
|
- |
|
|
|
2,675,000 |
|
|
|
267 |
|
|
|
(213 |
) |
|
|
- |
|
|
|
- |
|
|
|
- |
|
Stock-based compensation - options |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
1,117,335 |
|
|
|
- |
|
|
|
- |
|
|
|
1,117,335 |
|
Stock-based compensation - warrants |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
1,603,219 |
|
|
|
- |
|
|
|
- |
|
|
|
1,603,219 |
|
Stock-based compensation - restricted shares |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
30,938 |
|
|
|
- |
|
|
|
- |
|
|
|
30,938 |
|
Gain on extinguishment of related party convertible note |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
2,667,903 |
|
|
|
- |
|
|
|
- |
|
|
|
2,667,903 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss for the period |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(4,754,175 |
) |
|
|
(4,754,175 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance - June 30, 2022 |
|
|
5,875,000 |
|
|
$ |
588 |
|
|
|
3,075,000 |
|
|
$ |
307 |
|
|
|
770,000 |
|
|
$ |
77 |
|
|
|
24,788,132 |
|
|
$ |
2,479 |
|
|
$ |
36,376,832 |
|
|
$ |
- |
|
|
$ |
(17,246,906 |
) |
|
$ |
19,133,377 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock-based compensation - options |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
1,139,018 |
|
|
|
- |
|
|
|
- |
|
|
|
1,139,018 |
|
Stock-based compensation - warrants |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
Stock-based compensation - restricted shares |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
30,937 |
|
|
|
- |
|
|
|
- |
|
|
|
30,937 |
|
Gain on extinguishment of related party convertible note |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss for the period |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(3,144,435 |
) |
|
|
(3,144,435 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance - September 30, 2022 |
|
|
5,875,000 |
|
|
$ |
588 |
|
|
|
3,075,000 |
|
|
$ |
307 |
|
|
|
770,000 |
|
|
$ |
77 |
|
|
|
24,788,132 |
|
|
$ |
2,479 |
|
|
$ |
37,546,787 |
|
|
$ |
- |
|
|
|
(20,391,341
|
) |
|
$ |
17,158,897 |
|
6 |
|
|
2022 |
|
|
2021 |
|
||
CASH FLOW FROM OPERATING ACTIVIITES |
|
|
|
|
|
|
||
Net loss |
|
$ |
(9,234,877 |
) |
|
$ |
(6,576,372 |
) |
Adjustments to reconcile net loss to net cash (used in) provided by operating activities |
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
1,520,329 |
|
|
|
1,126,047 |
|
Amortization of discounts, premium and deferred costs |
|
|
1,869,152 |
|
|
|
1,342,181 |
|
Stock-based compensation |
|
|
4,906,152 |
|
|
|
5,305,700 |
|
Deferred tax provision |
|
|
610,033 |
|
|
|
(1,025,852 |
) |
Gain on disposal of fixed assets |
|
|
(303 |
) |
|
|
- |
|
Financing fee and bank charges for note payable and advances on revolving credit line |
|
|
3,775 |
|
|
|
- |
|
Realized gain on investment |
|
|
- |
|
|
|
(38,851 |
) |
Lease cost |
|
|
833 |
|
|
|
476 |
|
Legal fees paid out of proceeds from a note payable |
|
|
30,000 |
|
|
|
- |
|
Change in fair value of contingent earnout |
|
|
864,000 |
|
|
|
- |
|
Change in fair value of derivative liability |
|
|
97,000 |
|
|
|
- |
|
Changes in assets and liabilities |
|
|
|
|
|
|
|
|
Accounts receivable |
|
|
(2,637,969 |
) |
|
|
144,601 |
|
Prepaid expenses and other current assets |
|
|
(58,051 |
) |
|
|
(2,014 |
) |
Contract asset (liability) |
|
|
673,638 |
|
|
|
(569,610 |
) |
Payment of transaction costs in acquisition of SSI |
|
|
- |
|
|
|
(50,500 |
) |
Accounts payable and accrued expenses |
|
|
801,641 |
|
|
|
511,806 |
|
Net cash (used in) provided by operating activities |
|
|
(554,647 |
) |
|
|
167,612 |
|
|
|
|
|
|
|
|
|
|
CASH FLOWS FROM INVESTING ACTIVITES |
|
|
|
|
|
|
|
|
Cash received in acquisition of MFSI |
|
|
- |
|
|
|
93,240 |
|
Cash received in acquisition of Merrison, net of amounts paid |
|
|
- |
|
|
|
183,588 |
|
Cash received in acquisition of SSI, net of amounts paid |
|
|
- |
|
|
|
198,935 |
|
Cash paid in acquisition of LSG |
|
|
(250,000 |
) |
|
|
- |
|
Sale of investment |
|
|
- |
|
|
|
365,572 |
|
Purchase of fixed assets |
|
|
(92,436 |
) |
|
|
(5,346 |
) |
Net cash (used in) provided by investing activities |
|
|
(342,436 |
) |
|
|
835,989 |
|
|
|
|
|
|
|
|
|
|
CASH FLOWS FROM FINANCING ACTIVITES |
|
|
|
|
|
|
|
|
Proceeds from revolving credit line |
|
|
300,000 |
|
|
|
- |
|
Proceeds from issuance of preferred and common stock |
|
|
625,000 |
|
|
|
420,000 |
|
Proceeds from note s payable |
|
|
1,470,000 |
|
|
|
- |
|
Preferred stock dividend |
|
|
(70,449 |
) |
|
|
(3,320 |
) |
Proceeds from exercise of stock options |
|
|
12,000 |
|
|
|
- |
|
Repayment of convertible note payable - related parties |
|
|
(500,000 |
) |
|
|
(70,000 |
) |
Repayment of amounts due to seller |
|
|
(160,000 |
) |
|
|
- |
|
Repayment of line of credit, net |
|
|
- |
|
|
|
(3,460 |
) |
Repayment of note payable |
|
|
(943,995 |
) |
|
|
(104,244 |
) |
Net cash provided by financing activities |
|
|
732,556 |
|
|
|
238,976 |
|
|
|
|
|
|
|
|
|
|
NET (DECREASE) INCREASE IN CASH |
|
|
(164,527 |
) |
|
|
1,242,577 |
|
|
|
|
|
|
|
|
|
|
CASH - BEGINNING OF PERIOD |
|
|
2,017,915 |
|
|
|
2,412,382 |
|
|
|
|
|
|
|
|
|
|
CASH - END OF PERIOD |
|
$ |
1,853,388 |
|
|
$ |
3,654,959 |
|
|
|
|
|
|
|
|
|
|
SUPPLEMENTAL DISCLOSURES |
|
|
|
|
|
|
|
|
Cash paid for interest expense |
|
$ |
559,234 |
|
|
$ |
474,414 |
|
Cash paid for income taxes |
|
$ |
118,885 |
|
|
$ |
16,400 |
|
|
|
|
|
|
|
|
|
|
SUMMARY OF NON-CASH ACTIVITIES: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt discount on note payable applied to obligation to issue common stock |
|
$ |
500,000 |
|
|
$ |
- |
|
Adjustment to contingent consideration and customer relationships |
|
$ |
275,000 |
|
|
$ |
- |
|
Gain on extinguishment of convertible note payable - related party applied to APIC |
|
$ |
2,667,903 |
|
|
$ |
- |
|
Common shares issued for obligation to issue common stock |
|
$ |
533,750 |
|
|
$ |
- |
|
Derivative liability recognized as discount of note payable |
|
$ |
692,000 |
|
|
$ |
- |
|
Deferred issuance costs recognized for note payable |
|
$ |
59,300 |
|
|
$ |
- |
|
Fair value adjustment recognized on issuance of common stock in Securities Purchase Agreement |
|
$ |
93,000 |
|
|
$ |
- |
|
Common shares issued in conversion of Series B Preferred shares |
|
$ |
5,350 |
|
|
$ |
- |
|
Cancellation of shares offsetting acquisition of MFSI |
|
$ |
- |
|
|
$ |
400,000 |
|
7 |
· |
Corvus Consulting, LLC (“Corvus”), |
· |
Mainnerve Federal Services, Inc. dba MFSI Government Group (“MFSI), |
· |
Merrison Technologies, LLC (“Merrison”), |
· |
Specialty Systems, Inc. (“SSI”), |
· |
the business assets of Pax River from The Albers Group (“Pax River”), and |
· |
Lexington Solutions Group, LLC (“LSG”). |
8 |
9 |
|
|
2022 |
|
|
2021 |
|
||
Revenue: |
|
|
|
|
|
|
||
Time and material |
|
$ |
17,924,100
|
|
|
$ |
10,860,224 |
|
Firm fixed price |
|
|
3,607,597
|
|
|
|
2,820,041 |
|
Cost plus fixed fee |
|
|
10,634,407
|
|
|
|
1,837,869 |
|
Other |
|
|
-
|
|
|
|
69,112 |
|
Total |
|
$ |
32,166,104
|
|
|
$ |
15,587,246 |
|
10 |
11 |
Cash |
|
$ |
93,240 |
|
Accounts receivable |
|
|
33,540 |
|
Unbilled receivable |
|
|
45,316 |
|
Other assets |
|
|
329,509 |
|
Right of use asset – operating lease |
|
|
14,862 |
|
Customer relationships |
|
|
348,000 |
|
Non-compete agreement |
|
|
4,000 |
|
Goodwill |
|
|
685,072 |
|
Deferred tax liability |
|
|
(97,419 |
) |
Line of credit |
|
|
(12,249 |
) |
Lease liability – operating lease |
|
|
(13,862 |
) |
Accounts payable and accrued expenses |
|
|
(47,572 |
) |
Net assets acquired |
|
$ |
1,382,437 |
|
Common stock |
|
$ |
1,382,437 |
|
12 |
Cash |
|
$ |
183,588 |
|
Accounts receivable and unbilled receivables |
|
|
391,049 |
|
Customer relationships |
|
|
322,000 |
|
Non-compete agreements |
|
|
7,000 |
|
Trademarks |
|
|
164,000 |
|
Backlog |
|
|
115,000 |
|
Goodwill |
|
|
780,730 |
|
Deferred tax liability |
|
|
(243,730 |
) |
Accounts payable and accrued expenses |
|
|
(102,354 |
) |
Net assets acquired |
|
$ |
1,617,283 |
|
Common stock |
|
$ |
1,595,000 |
|
Cash |
|
|
22,283 |
|
$ |
1,617,283 |
|
13 |
Cash |
|
$ |
998,935 |
|
Accounts receivable and unbilled receivables |
|
|
2,222,004 |
|
Prepaid expenses |
|
|
147,600 |
|
Other asset |
|
|
6,750 |
|
Furniture and equipment |
|
|
148,931 |
|
Right of use asset – operating lease |
|
|
169,063 |
|
Customer relationships |
|
|
3,102,000 |
|
Non-compete agreements |
|
|
65,000 |
|
Trademarks |
|
|
367,000 |
|
Backlog |
|
|
50,000 |
|
Goodwill |
|
|
8,461,150 |
|
Deferred tax liability |
|
|
(880,150 |
) |
Lease liability – operating lease |
|
|
(167,333 |
) |
Contract liability |
|
|
(226,591 |
) |
Accounts payable and accrued expenses |
|
|
(1,134,509 |
) |
Net assets acquired |
|
$ |
13,329,850 |
|
Common stock |
|
$ |
7,872,850 |
|
Seller note |
|
|
400,000 |
|
Cash |
|
|
800,000 |
|
Contingent earnout |
|
|
257,000 |
|
Lender financing |
|
|
4,000,000 |
|
|
|
$ |
13,329,850 |
|
14 |
Customer relationships (contracts) (a) |
|
$ |
2,400,000 |
|
Net assets acquired |
|
$ |
2,400,000 |
|
Common stock |
|
$ |
1,925,000 |
|
Contingent consideration represented by obligation to issue shares (a) |
|
|
275,000 |
|
Cash (included in amounts due to seller as of December 31, 2021) (b) |
|
|
200,000 |
|
$ |
2,400,000 |
|
(a) |
It was determined that on March 31, 2022, that the requirements under section 1.5(b) of the acquisition agreement had not been achieved, and as a result the contingent consideration to issue the additional 68,750 common shares valued at $275,000 would not be issued. The Company adjusted the customer relationships by the $275,000 down to $2,125,000. |
(b) |
As of September 30, 2022, $160,000 was paid to the seller and the balance owed as of September 30, 2022 is $40,000. |
Receivable from Seller |
|
$ |
413,609 |
|
Due from Employee/Travel Advance |
|
|
5,000 |
|
Miscellaneous license |
|
|
2,394 |
|
Customer relationships |
|
|
785,000 |
|
Non-compete agreements |
|
|
10,000 |
|
Backlog |
|
|
489,000 |
|
Goodwill |
|
|
1,471,000 |
|
Net assets acquired |
|
$ |
3,176,003 |
|
Common stock (600,000 shares issued May 4, 2022) |
|
$ |
2,280,000 |
|
Holdback shares (25,000 shares due six months after the closing date) (in obligation to issue common stock) |
|
|
95,000 |
|
Cash |
|
|
250,000 |
|
Due to seller (cash) |
|
|
551,003 |
|
|
|
$ |
3,176,003 |
|
15 |
For the nine months ended September 30, 2022 |
|
|||
Revenues |
|
$ |
33,685,580 |
|
Net loss |
|
$ |
(7,843,711 |
) |
Net loss per share - basic |
|
$ |
(0.33 |
) |
For the nine months ended September 30, 2021 |
|
|
|
|
Revenues |
|
$ |
20,333,508 |
|
Net loss |
|
$ |
(127,660 |
) |
Net loss per share - basic |
|
$ |
(0.00 |
) |
|
|
September 30, 2022 (unaudited) |
|
|
December 31, 2021 |
|
||
Equipment |
|
$ |
96,986 |
|
|
$ |
60,148 |
|
Furniture |
|
|
32,574 |
|
|
|
32,574 |
|
Software |
|
|
44,746 |
|
|
|
- |
|
Leasehold improvements |
|
|
83,266 |
|
|
|
75,265 |
|
Total fixed assets |
|
|
257,572 |
|
|
|
167,987 |
|
Accumulated depreciation |
|
|
(66,630 |
) |
|
|
(22,195 |
) |
Fixed assets, net |
|
$ |
190,942 |
|
|
$ |
145,792 |
|
16 |
|
|
|
|
|
September 30, 2022 (unaudited) |
|
|
December 31, 2021 |
|
|||
Customer relationships |
|
|
4.5– 15 years |
|
|
$ |
9,535,000 |
|
|
$ |
9,025,000 |
|
Trade name |
|
|
4.5 years |
|
|
|
266,000 |
|
|
|
266,000 |
|
Trademark |
|
|
10-15 years |
|
|
|
533,863 |
|
|
|
533,863 |
|
Backlog |
|
|
2-5 years |
|
|
|
1,436,000 |
|
|
|
947,000 |
|
Non-compete agreement |
|
|
3-5 years |
|
|
|
684,000 |
|
|
|
674,000 |
|
|
|
|
|
|
|
|
12,454,863 |
|
|
|
11,445,863 |
|
Accumulated amortization |
|
|
|
|
|
|
(5,323,003 |
) |
|
|
(3,850,264 |
) |
Intangible assets, net |
|
|
|
|
|
$ |
7,131,860 |
|
|
$ |
7,595,599 |
|
September 30, 2023 |
|
$ |
1,969,588 |
|
September 30, 2024 |
|
|
1,653,245 |
|
September 30, 2025 |
|
|
985,482 |
|
September 30, 2026 |
|
|
721,751 |
|
September 30, 2027 |
|
|
526,950 |
|
Thereafter |
|
|
1,274,844 |
|
Total |
|
$ |
7,131,860 |
|
|
|
2022 |
|
|
2021 |
|
||
Balance – beginning of period |
|
$ |
14,062,964 |
|
|
$ |
4,136,011 |
|
Additions |
|
|
1,471,000 |
|
|
|
9,926,953 |
|
Disposals |
|
|
- |
|
|
|
- |
|
Impairment |
|
|
- |
|
|
|
- |
|
|
|
$ |
15,533,964 |
|
|
$ |
14,062,964 |
|
17 |
|
|
September 30, 2022 (unaudited) |
|
|
December 31, 2021 |
|
||
Convertible note payable with a trust related to one of the Company’s directors, convertible at $0.26 per share, at 5% interest (extinguished on April 4, 2022 for new note) (a) |
|
$ |
- |
|
|
|
4,209,617 |
|
Convertible note payable with a trust related to one of the Company’s directors, convertible at $0.26 per share, at 5% interest (amended April 4, 2022) |
|
|
3,709,617 |
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
Total Convertible Notes Payable – Related Parties |
|
$ |
3,709,617 |
|
|
$ |
4,209,617 |
|
Add: Premiums recorded on convertible note due to fair value adjustment at date of acquisition of Corvus |
|
|
- |
|
|
|
2,569 |
|
Less: BCF Discount |
|
|
(3,012,791 |
) |
|
|
(1,407,002 |
) |
|
|
$ |
696,826 |
|
|
$ |
2,805,184 |
|
(a) |
On February 1, 2021, the two promissory notes with The Buckhout Charitable Remainder Trust (Laurie Buckhout – Trustee), were combined into one new note in the principal balance of $4,279,617, that has a new maturity date of February 1, 2024. The interest rate remains at 5% per annum, and the note now includes monthly principal payments of $10,000. The conversion terms have remained at $0.26 per share. It was determined that under ASC 470, the debt amendment was considered a modification. Then again on August 12, 2021, the convertible note was amended to remove the principal payments and extend the debt further to September 30, 2024. It was determined that under ASC 470, the debt amendment was considered an extinguishment. The result of the extinguishment netted a gain of $2,667,903 that was recorded as additional paid in capital as the transaction was with a related party. |
18 |
|
|
September 30, 2022 (unaudited) |
|
|
December 31, 2021 |
|
||
Note payable at 7% originally due November 2023, now maturing September 30, 2024 (a) |
|
$ |
5,600,000 |
|
|
$ |
5,600,000 |
|
Note payable at 10% interest dated February 28, 2022 and matures the earlier of (i) September 30, 2024 or (ii) the acceleration of the obligations as contemplated under the promissory note including the successful completion of an equity offering of at least $15,000,000 (b) |
|
|
500,000 |
|
|
|
- |
|
Convertible note payable, convertible at $1.60 per share, at 7%, maturing April 4, 2023 (c) |
|
|
1,050,000 |
|
|
|
- |
|
Term note payable , at prime plus 3% interest , applied on a deferred basis (7.75% at September 30, 2022 and 6.25% at December 31, 2021) maturing August 11, 2024 |
|
|
2,644,280 |
|
|
|
3,588,374 |
|
|
|
|
|
|
|
|
0 |
|
Total Notes Payable |
|
|
9,794,380 |
|
|
|
9,188,374 |
|
Less: Debt Discount |
|
|
(1,321,959 |
) |
|
|
(796,565 |
) |
|
|
$ |
8,472,421 |
|
|
$ |
8,391,809 |
|
(a) |
on August 12, 2021, the note payable was amended to extend the debt to September 30, 2024. It was determined that under ASC 470, the debt amendment was considered a modification. |
(b) |
on February 28, 2022, the Company was obligated to issue 125,000 shares of common stock as further consideration for making this loan to the Company. The shares were issued in April 2022. |
(c) |
on April 4, 2022, the Company entered into a Securities Purchase Agreement (“SPA”) with Crom. The SPA includes (a) a Convertible Promissory Note dated April 4, 2022 in the amount of $1,050,000 at 7% interest per annum. This note matures April 4, 2023 (one-year) and is convertible at a conversion price of $1.60 per share; (b) the issuance of 656,250 warrants that mature April 4, 2027, with an exercise price of $1.84 per share; and (c) the issuance of 1,250,000 common shares at $0.40 per share ($500,000), the proceeds of which were paid to The Buckhout Charitable Remainder Trust for the First Payment. In addition, Crom was issued 125,000 common shares as further inducement to enter into the SPA. The Company analyzed the debt instrument with Crom, under ASC 815-10, and determined that the conversion option should be separated from the host debt instrument (i.e., bifurcated) and classified as a derivative liability, along with the value of the warrants as a derivative liability at the inception date of April 4, 2022. The fair value of the derivative liabilities at inception were reflected as a discount on the note, along with an original issue discount of $50,000, and the discount of $93,000 on the 1,250,000 shares of common stock issued to Crom that had a fair value of $593,000 which exceeded the $500,000 paid by Crom that will be amortized over the life of the note (one year). The derivative liability is marked to market each reporting period, and the Company recognized a loss on the change in fair value of the derivative liabilities of $173,000 from April 4, 2022 to September 30, 2022. |
September 30, 2023 |
|
$ |
1,960,121 |
|
September 30, 2024 |
|
|
6,512,300 |
|
Total |
|
$ |
8,472,421 |
|
19 |
|
|
September 30, 2022 (unaudited) |
|
|
December 31, 2021 |
|
||
Note payable at 5% due December 31, 2024, in connection with the acquisition of SSI |
|
$ |
400,000 |
|
|
$ |
400,000 |
|
20 |
21 |
|
|
Nine Months Ended September 30, 2022 |
|
Year Ended December 31, 2021 |
|
||||||||||
|
|
Number |
|
|
Weighted Average Exercise Price |
|
Number |
|
Weighted Average Exercise Price |
|
|||||
Beginning balance |
|
|
3,161,568 |
|
|
$ |
1.60 |
|
|
1,090,717 |
|
|
$ |
0.00 |
|
Granted |
|
|
1,017,268 |
|
|
|
2.60 |
|
|
2,070,851 |
|
|
|
2.40 |
|
Exercised Cashless |
|
|
- |
|
|
|
- |
|
|
- |
|
|
|
- |
|
Forfeited |
|
|
- |
|
|
|
- |
|
|
- |
|
|
|
- |
|
Expired |
|
|
- |
|
|
|
- |
|
|
- |
|
|
|
- |
|
Ending balance |
|
|
4,178,836 |
|
|
$ |
1.79 |
|
|
3,161,568 |
|
|
$ |
1.60 |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Warrants exercisable |
|
|
4,178,836 |
|
|
|
|
|
3,161,568 |
|
|
|
|
||
Intrinsic value of warrants |
|
$ |
10,468,925 |
|
|
|
|
$ |
5,706,473 |
|
|
|
|
||
Weighted Average Remaining Contractual Life (Years) |
|
|
5.26 |
|
|
|
|
|
|
|
|
|
|
|
|
22 |
Nine Months Ended September 30, 2022 | Year Ended December 31, 2021 | |||||||||||||||
Number | Weighted Average Exercise Price | Number | Weighted Average Exercise Price | |||||||||||||
Beginning balance | 4,594,688 | $ | 2.094 | 1,856,250 | $ | 0.80 | ||||||||||
Granted | 2,535,000 | 3.60 | 4,087,500 | 2.40 | ||||||||||||
Exercised | (15,000 | ) | (0.80 | ) | (10,000 | ) | (0.80 | ) | ||||||||
Forfeited | (289,688 | ) | (0.60 | ) | (1,339,062 | ) | (0.60 | ) | ||||||||
Expired | - | - | - | - | ||||||||||||
Ending balance | 6,825,000 | $ | 0.1368 | 4,594,688 | $ | 2.094 | ||||||||||
Vested options | 1,610,506 | 1,410,938 | ||||||||||||||
Nonvested options | 5,214,494 | 3,183,750 | ||||||||||||||
Intrinsic value of options | $ | 12,876,650 | $ | 6,140,313 | ||||||||||||
Weighted Average Remaining Contractual Life (Years) | 6.14 | 6.21 |
23 |
Nine Months Ended September 30, 2022 | Year Ended December 31, 2021 | |||||||
Expected term | 7 years | 7 years | ||||||
Expected volatility | 114 – 126 | 135 – 177 | % | |||||
Expected dividend yield | - | - | ||||||
Risk-free interest rate | 2.00 – 2.85 | 0.10 | % |
Fair Value Measurements at September 30, 2022 | ||||||||||||||||
Level 1 | Level 2 | Level 3 | Total | |||||||||||||
Crom Derivative Liabilities | $ | - | $ | - | $ | 789,000 | $ | 789,000 | ||||||||
Contingent Earnout | $ | - | $ | - | $ | 1,121,000 | $ | 1,121,000 | ||||||||
Total | $ | - | $ | - | $ | 1,910,000 | $ | 1,910,000 |
Fair Value Measurements at December 31, 2021 | ||||||||||||||||
Level 1 | Level 2 | Level 3 | Total | |||||||||||||
Crom Derivative Liabilities | $ | - | $ | - | $ | - | $ | - | ||||||||
Contingent Earnout | $ | - | $ | - | $ | 257,000 | $ | 257,000 | ||||||||
Total | $ | - | $ | - | $ | 257,000 | $ | 257,000 |
September 30, 2022 (unaudited) | December 31, 2021 | Inception | ||||||||||
Fair value of conversion option of Crom Cortana Fund LLC convertible note | $ | (345,000 | ) | $ | - | $ | (314,000 | ) | ||||
Fair value of 656,250 warrants on April 4, 2022 | (444,000 | ) | - | (378,000 | ) | |||||||
$ | (789,000 | ) | $ | - | (692,000 | ) |
24 |
Beginning balance as of December 31, 2021 |
|
$ |
- |
|
Issuances of convertible note/warrants – derivative liabilities |
|
|
(692,000 |
) |
Warrants exchanged for common stock |
|
|
- |
|
Change in fair value of warrant derivative liabilities |
|
|
(97,000 |
) |
Ending balance as of September 30, 2022 |
|
$ |
(789,000 |
) |
|
|
September 30, 2022 |
|
|
Inception – April 4, 2022 |
|
||
Expected term – conversion option |
|
|
0.51 years |
|
|
|
1 year |
|
Expected term - warrants |
|
|
4.51 years |
|
|
|
5 years |
|
Stock price as of Measurement Date |
|
$ |
4.30 |
|
|
$ |
3.80 |
|
Equity volatility - unadjusted |
|
|
284.80 |
% |
|
|
278.80 |
% |
Volatility haircut |
|
|
5.00 |
% |
|
|
5.00 |
% |
Selected volatility – post haircut |
|
|
115.0 |
% |
|
|
112.60 |
% |
Senior unsecured synthetic credit rating |
|
|
CCC + |
|
|
|
CCC + |
|
B- market yield |
|
|
7.90 |
% |
|
|
4.50 |
% |
OAS differential between CCC+ and B- bonds |
|
|
458 |
|
|
|
383 |
bps
|
Risk adjusted rate |
|
|
12.50 |
% |
|
|
8.30 |
% |
Risk-free interest rate |
|
|
3.90 |
% |
|
|
1.70 |
% |
25 |
26 |
· | On October 13, 2022, the Company effectuated the Reverse Stock Split and commenced trading of its common stock on the NYSE American LLC. |
· | On October 17, 2022, the Company closed on its public offering of 1,500,000 shares of common stock consisting of 1,350,000 shares sold by the Company and 150,000 shares sold by certain selling stockholders, at a public offering price of $2.00 per share. In connection therewith, the Company issu ed 1,231 shares of common stock to stockholders with fractional shares resulting from the reverse stock split. |
· | On October 17, 2022 the Company issued a total of 15,375,000 Common Stock in connection with the conversion of all its Series B preferred stock outstanding in connection with its public offering. |
· | In October 2022, t he Company made an advanced principal payment of $500,000 to The Buckhout Charitable Remainder Trust. |
· | In October 2022 , the Company made a payment of $250,000 pursuant to the terms of the LSG Business Acquisition Agreement. |
· | In November 2022, t he Company made an advanced principal payment of $100,000 on the Eisiminger note. |
· | On November 7, 2022, the Company announced the signing of a non-binding letter of intent to acquire an East-Coast-based government contractor. |
27 |
|
· |
Enterprise – We provide capabilities that enable the internal operations of a government agency. This includes digital solutions, such as business systems, agency-unique applications, investigative solutions, and enterprise IT. For example, Castellum customizes, implements, and maintains commercial-off-the-shelf (“COTS”) and customer enterprise resource planning (“ERP”) systems. This includes, financial, human capital, and supply chain management systems. Castellum also designs, integrates, deploys, and sustains enterprise-wide IT systems in a variety of models. |
28 |
|
· |
Mission – Castellum provides capabilities that enable the execution of a government agency’s primary function, or “mission”. For example, we support strategic and tactical mission customers with capabilities in areas such as command and control, communications, intelligence collection and analysis, signal intelligence (“SIGINT”), electronic warfare (“EW”), and cyber operations. Castellum develops tools and offerings in an open, software-defined architecture with multi-domain and multi-mission capabilities. |
|
· |
Expertise – Castellum provides expertise to both enterprise and mission customers. For enterprise customers, we deliver talent with the specific technical and functional knowledge to support internal agency operations. And for mission customers, we deliver talent with technical and domain knowledge to support the execution of an agency’s mission. We also deliver actionable intelligence through multi-source collection, aggregation, and analysis. |
|
· |
Technology – Castellum delivers technology to both enterprise and mission customers. For enterprise customers, technology includes developing and implementing digital solutions (business systems, agency-unique applications) and end-to-end enterprise IT systems. We continually advance infrastructure through migration to the cloud network modernization, active cyber defense, and the application of data operations and analytics. For mission customers, technology includes developing and deploying multi-domain offerings for signals intelligence, resilient communications, fee space optical communications, electronic warfare, and cyber operations. Castellum invests ahead of customer needs with research and development to generate unique intellectual property and differentiated technology addressing critical national security mission needs. |
29 |
· |
the three months ended September 30, 2022 compared to the three months ended September 30, 2021. |
· |
the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021. |
30 |
· |
Indirect costs consist of expenses generally associated with bonuses and fringe benefits, including employee health and medical insurance, 401k matching contributions, and payroll taxes. |
· |
Overhead consists of expenses associated with the support of operations or production, including labor for management of contracts, operations, training, supplies, and certain facilities to perform customer work. |
· |
General and administrative expenses consist primarily of corporate and administrative labor expenses, administrative bonuses, legal expenses, IT expenses, and insurance expenses. |
31 |
32 |
THREE MONTHS ENDED |
|
|
||||||||||||||
SEPTEMBER 30, |
|
|
Change |
|
||||||||||||
2022 |
|
|
2021 |
|
|
Amount |
|
|
% |
|
||||||
Revenues |
|
$ |
11,120,712 |
|
|
$ |
7,378,094 |
|
|
$ |
3,742,618 |
|
|
|
51 |
% |
Cost of revenues |
|
|
6,474,261 |
|
|
|
4,309,439 |
|
|
|
2,164,822 |
|
|
|
50 |
% |
Gross Profit |
|
|
4,646,451 |
|
|
|
3,068,655 |
|
|
|
1,577,796 |
|
|
|
51 |
% |
Operating expenses: |
|
|
|
|||||||||||||
Indirect costs |
|
|
2,130,513 |
|
|
|
738,239 |
|
|
|
1,392,274 |
|
|
|
189 |
% |
Overhead |
|
|
407,804 |
|
|
|
248,540 |
|
|
|
159,264 |
|
|
|
64 |
% |
General and administrative expenses |
|
|
3,297,319 |
|
|
|
6,682,034 |
|
|
|
( 3,384,715 |
) |
|
|
(51 |
)% |
Loss from change in fair value of contingent earnout |
|
|
864,000 |
|
|
|
- |
|
|
|
864,000 |
|
|
|
100 |
% |
Total operating expenses |
|
|
6,699,636 |
|
|
|
7,668,813 |
|
|
|
( 969,177 |
) |
|
|
(13 |
)% |
Income (loss) from operations: |
|
|
(2, 053,185 |
) |
|
|
(4,600,158 |
) |
|
|
2,546,973 |
|
|
|
(55 |
)% |
|
||||||||||||||||
Other income (expense) |
|
|
( 902,314 |
) |
|
|
(648,175 |
) |
|
|
( 254,139 |
) |
|
|
39 |
% |
|
||||||||||||||||
Income (loss) before income taxes and preferred stock dividends |
|
|
( 2,955,499 |
) |
|
|
(5,248,333 |
) |
|
|
2, 292,834 |
|
|
|
(44 |
)% |
|
||||||||||||||||
Income tax benefit (expense) |
|
|
(159,025) |
|
|
|
328,735 |
|
|
|
(487,760 |
) |
|
|
(148 |
)% |
Preferred stock dividend |
|
|
29,911 |
|
|
|
3,320 |
|
|
|
26,591 |
|
|
|
801 |
% |
Net loss |
|
$ |
(3,144,435 |
) |
|
$ |
(4,922,918 |
) |
|
$ |
1,778,483 |
|
|
|
-36 |
% |
33 |
NINE MONTHS ENDED |
|
|
||||||||||||||
SEPTEMBER 30, |
|
|
Change |
|
||||||||||||
2022 |
|
|
2021 |
|
|
Amount |
|
|
% |
|
||||||
Revenues |
|
$ |
32,166,104 |
|
|
$ |
15,587,246 |
|
|
$ |
16,578,858 |
|
|
|
106 |
% |
Cost of revenues |
|
$ |
18,698,820 |
|
|
|
8,921,153 |
|
|
|
9,777,667 |
|
|
|
110 |
% |
Gross Profit |
|
$ |
13,467,284 |
|
|
|
6,666,093 |
|
|
|
6,801,191 |
|
|
|
102 |
% |
Operating expenses: |
|
|
|
|||||||||||||
Indirect costs |
|
|
7,458,319 |
|
|
|
1,512,370 |
|
|
|
5,945,949 |
|
|
|
393 |
% |
Overhead |
|
|
1,167,346 |
|
|
|
431,987 |
|
|
|
735,359 |
|
|
|
170 |
% |
General and administrative expenses |
|
|
9, 633,064 |
|
|
|
10,389,922 |
|
|
|
( 756 , 858 |
) |
|
|
( 7 |
)% |
Loss from change in fair value of contingent earnout |
|
|
864,000 |
|
|
|
- |
|
|
|
864,000 |
|
|
|
100 |
%
|
Total operating expenses |
|
|
19,122,729 |
|
|
|
12,334,279 |
|
|
|
6,788,450 |
|
|
|
55 |
% |
Income (loss) from operations: |
|
|
( 5,655,445 |
) |
|
|
(5,668,186 |
) |
|
|
12,741 |
|
|
|
0 |
% |
|
||||||||||||||||
Other income (expense) |
|
|
(2, 676 ,612 |
) |
|
|
(1,799,181 |
) |
|
|
( 877,431 |
) |
|
|
49 |
% |
|
||||||||||||||||
Income (loss) before income taxes and preferred stock dividends |
|
|
(8, 332,057 |
) |
|
|
(7,467,367 |
) |
|
|
( 864,690 |
) |
|
|
( 1 2 |
)% |
|
||||||||||||||||
Income tax benefit (expense) |
|
|
( 902,820 |
) |
|
|
890,995 |
|
|
|
(1, 793,815 |
) |
|
|
( 201 |
)% |
Preferred stock dividend |
|
|
70,447 |
|
|
|
3,320 |
|
|
|
67,127 |
|
|
|
2022 |
% |
Net loss |
|
$ |
(9, 305,324 |
) |
|
$ |
(6,579,692 |
) |
|
$ |
(2, 725,632 |
) |
|
|
41 |
% |
34 |
· |
Funded Backlog - Funded backlog represents the revenue value of orders for services under existing contracts for which funding is appropriated or otherwise authorized less revenue previously recognized on these contracts. |
· |
Unfunded Backlog - Unfunded backlog represents the revenue value of orders (including optional orders) for services under existing contracts for which funding has not been appropriated or otherwise authorized. |
· |
Priced Options - Priced contract options represent 100% of the revenue value of all future contract option periods under existing contracts that may be exercised at our clients’ option and for which funding has not been appropriated or otherwise authorized. |
Funded |
|
$ |
15,687,679 |
|
Unfunded |
|
|
10,372,982 |
|
Priced Options |
|
|
62,093,312 |
|
Total Backlog |
|
$ |
88,153,973 |
|
35 |
Nine Months Ended September 30, |
|
|
Change |
|
||||||||||||
2022 |
|
|
2021 |
|
|
Amount |
|
|
% |
|
||||||
Net cash provided (used) by operating activities |
|
$ |
(554,647 |
) |
|
$ |
167,612 |
|
|
$ |
(722,259 |
) |
|
|
-431 |
% |
Net cash provided (used) by investing activities |
|
|
(342,436 |
) |
|
|
835,989 |
|
|
$ |
(1,178,425 |
) |
|
|
-141 |
% |
Net cash provided (used) by financing activities |
|
|
732,556 |
|
|
|
238,976 |
|
|
$ |
493,580 |
|
|
|
207 |
% |
Change in cash |
|
$ |
(164,527 |
) |
|
$ |
1,242,577 |
|
|
$ |
(1,407,104 |
) |
|
|
-113 |
% |
36 |
37 |
38 |
39 |
|
· |
limited operating history at our current scale; |
|
· |
our ability to raise capital to develop our business and fund our operations; |
|
· |
our ability to anticipate and adapt to developing markets; |
|
· |
acceptance by our customers; |
|
· |
limited marketing experience; |
|
· |
competition from competitors with substantially greater financial resources and assets; and |
|
· |
the ability to identify, attract, and retain qualified personnel. |
40 |
41 |
· |
selling to governmental agencies can be highly competitive, expensive and time consuming, often requiring significant upfront time and expense without any assurance that such efforts will generate a sale. Our existing contracts typically expire after some period of time and must be “re-competed.” There is no guarantee that we will win such re-compete efforts; |
· |
government certification requirements applicable to our products may change and in doing so restrict our ability to sell into the U.S. Federal government (“USG”) sector until we have attained the revised certification; |
· |
government demand and payment for our products and services may be impacted by public sector budgetary cycles and funding authorizations, with funding reductions or delays adversely affecting public sector demand for our products and services; |
· |
governments can generally terminate our contracts “for convenience” meaning we could lose part or all of our revenue on short notice; |
· |
governments routinely investigate and audit government contractors’ administrative processes, and any unfavorable audit could result in the government refusing to continue buying our platform, which would adversely impact our revenue and results of operations, or institute fines or civil or criminal liability if the audit uncovers improper or illegal activities; and |
· |
when we are a subcontractor, we have less control over the execution and success of the contract with the government. |
42 |
|
· |
the Federal Acquisition Regulation (“FAR”), and agency regulations supplemental to FAR, which regulate the formation, administration, and performance of USG contracts; |
|
· |
the False Statements Act, which imposes civil and criminal liability for making false statements to the USG; |
|
· |
the Truthful Cost or Pricing Data Statute (formerly known as the “Truth in Negotiations Act”), which requires certification and disclosure of cost and pricing data in connection with the negotiation of certain contracts, modifications, or task orders; |
|
· |
the Procurement Integrity Act, which regulates access to competitor bid and proposal information and certain internal government procurement sensitive information, and our ability to provide compensation to certain former government procurement officials; |
|
· |
laws and regulations restricting the ability of a contractor to provide gifts or gratuities to employees of the USG, including The Foreign Corrupt Practices Act of 1977 (the “FCPA”) which prohibits U.S. citizens and entities from bribing foreign government officials to benefit their business interests; |
|
· |
post-government employment laws and regulations, which restrict the ability of a contractor to recruit and hire current employees of the USG and deploy former employees of the USG; |
|
· |
laws, regulations, and executive orders restricting the handling, use, and dissemination of information classified for national security purposes or determined to be “controlled unclassified information” or “for official use only,” and the export of certain products, services, and technical data, including requirements regarding any applicable licensing of our employees involved in such work; |
|
· |
laws, regulations, and executive orders regulating the handling, use, and dissemination of personally identifiable information in the course of performing a USG contract; |
|
· |
international trade compliance laws, regulations, and executive orders that prohibit business with certain sanctioned entities and require authorization for certain exports or imports in order to protect national security and global stability, including The International Traffic in Arms Regulations (“ITAR”) that controls the manufacture, sale, and distribution of defense and space-related articles and services as defined in the United States Munitions List (“USML”); |
|
· |
laws, regulations, and executive orders governing organizational conflicts of interest that may restrict our ability to compete for certain USG contracts because of the work that we currently perform for the USG or may require that we take measures such as firewalling off certain employees or restricting their future work activities due to the current work that they perform under a USG contract; |
|
· |
laws, regulations, and executive orders that impose requirements on us to ensure compliance with requirements and protect the USG from risks related to our supply chain such as compliance with Cybersecurity Maturity Model Certification (“CMMC”); |
|
· |
laws, regulations, and mandatory contract provisions providing protections to employees or subcontractors seeking to report alleged fraud, waste, and abuse related to a USG contract; |
|
· |
the Contractor Business Systems rule, which authorizes U.S. Department of Defense (“DoD”) agencies to withhold a portion of or payments if we are determined to have a significant deficiency in our accounting, cost estimating, purchasing, earned value management, material management and accounting, and/or property management system; and |
43 |
|
· |
the Cost Accounting Standards and Cost Principles, which impose accounting and allowability requirements that govern our right to reimbursement under certain cost-based USG contracts and require consistency of accounting practices over time. |
· |
cancel multi-year contracts and related orders if funds for contract performance for any subsequent year become unavailable; |
· |
claim rights in systems and software developed by us; |
· |
suspend or debar us from doing business with the USG or with a governmental agency; |
· |
impose fines and penalties and subject us to criminal prosecution; and |
· |
control or prohibit the export of our data technology or proprietary service solutions. |
44 |
45 |
|
· |
we bid on programs before the completion of their design, which may result in unforeseen technological difficulties and cost overruns; |
|
· |
we expend substantial cost and managerial time and efforts to prepare bids and proposals for contracts that we may not win; |
|
· |
we may be unable to estimate accurately the resources and cost structure that will be required to service any contract we win; and |
|
· |
we may encounter expense and delay if our competitors protest or challenge awards or contracts to us in competitive bidding, and any such protest or challenge could result in the resubmission of bids on modified specifications, or in termination, reduction, or modification of the awarded contract. |
46 |
47 |
48 |
49 |
|
· |
increased competition for acquisitions may increase the costs for our acquisitions; |
|
· |
unreasonable expectations of companies related to their perceived versus actual value; |
50 |
|
· |
our failure to discover material liabilities during the due diligence process, including the failure of prior owners of any acquired businesses or their employees to comply with applicable laws or regulations, such as the FAR and health, safety, and environmental laws, or their failure to fulfill their contractual obligations to the USG or other customers; |
|
· |
our acquisitions may not ultimately strengthen our competitive position or allow us to achieve our goals, and any acquisitions we complete could be viewed negatively by our customers, analysts, and investors; |
|
· |
acquisition financing may not be available on reasonable terms or at all; |
|
· |
failure to properly integrate our acquisitions with our existing business thereby preventing the realization of potential synergies with the acquired business; and |
|
· |
debt incurred in making acquisitions may reduce our financial flexibility to pursue other opportunities or invest in internal growth. |
51 |
· |
whether our results of operations meet the expectations of securities analysts or investors; |
· |
departures of key personnel; |
· |
actual or anticipated changes in the expectations or securities analysts; |
· |
litigation involving us, our industry, or both; |
· |
regulatory developments in the U.S., foreign countries or both; |
· |
price and volume fluctuations in the overall stock market from time to time; |
· |
fluctuations in the trading volume of our shares or the size of the public float; |
· |
variations in our revenue and operating expenses; |
· |
market conditions in our industry and the economy as a whole; |
· |
actual or expected changes in our growth rates or our competitors’ growth rates; |
· |
developments or disputes concerning intellectual and proprietary rights; |
· |
developments in the financial markets and worldwide or regional economies; |
· |
variations in our financial results or those of companies that are perceived to be similar to us; |
· |
announcements by the government relating to regulations that govern our industry; |
· |
sales of our common stock or other securities by us or in the open market; |
· |
changes in the market valuations of other comparable companies; |
· |
general economic, industry, and market conditions; |
· |
major catastrophic events; and |
· |
the other factors described in this “Risk Factors” section. |
52 |
53 |
54 |
55 |
· |
the composition of our Board of Directors and, through it, any determination with respect to our business direction and policies, including the appointment and removal of officers; |
· |
any determination with respect to mergers or other business combinations; |
· |
our acquisition or disposition of assets; and |
· |
our corporate financing activities. |
56 |
(a) |
Recent Sales of Unregistered Securities. |
(b) |
Use of Proceeds from the Public Offering. |
(a) |
On August 30, 2022 the Registrant filed an Amended and Restated Articles of Incorporation (the “Restated Articles of Incorporation”) with the Secretary of State of Nevada. In connection with the Public Offering, the Company’s Board of Directors and stockholders approved the Restated Articles of Incorporation on July 27, 2022. The Restated Articles of Incorporation are attached hereto as Exhibit 3.1 and is incorporated herein by reference. |
(b) |
On and effective September 27, 2022 the Registrant’s Board of Directors adopted the Amended and Restated Bylaws of the Registrant (the “Restated Bylaws”), as follows: |
1. |
Set forth procedures with respect to stockholder nominations of directors and submissions of stockholder proposals at meetings of stockholders which requires a stockholder to provide advance written notice of a proposal to nominate a person for election to the Registrant’s Board of Directors; and |
2. |
Specify additional types of information and representations that a nominating stockholder or its proposed director nominee must provide to the Registrant in connection with a director nomination. |
57 |
|
|
|
|
|
Incorporated by Reference |
|||||
Exhibit Number |
|
Exhibit Title |
Form |
|
File Number |
|
Exhibit |
|
Filing Date |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
|
||
|
|
|
|
58 |
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|||||
59 |
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|||||
60 |
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
104 |
The cover page from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, has been formatted in Inline XBRL and contained in Exhibits 101 |
++ |
Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K because such information is (i) not material and (ii) the type of information the Company treats as confidential. The Company will furnish supplementally an unredacted copy of such exhibit to the Securities and Exchange Commission or its staff upon its request. |
61 |
Date: November 14, 2022 |
CASTELLUM, INC. |
|
|
|
/s/ Mark C. Fuller |
|
Mark C. Fuller |
|
Chief Executive Officer (Principal Executive Officer) |
|
|
|
/s/ David T. Bell |
|
David T. Bell |
|
Chief Financial Officer (Principal Financial Officer) |
62 |
Exhibit 10.23
EMPLOYMENT AGREEMENT
THIS EMPLOYMENT AGREEMENT (this “Agreement”), dated as of November 21, 2019 (the “Effective Date”), is by and between Corvus Consulting, LLC (the “Company”), and Laurie Buckhout (“Employee”).
RECITALS
A. The Employee is Trustee of The Buckhout Charitable Remainder Trust which is selling the Company to BioNovelus, Inc. (“BioNovelus”).
B. The Company and Employee desire to enter into this Agreement relating to Employee’s employment by the Company to assist the Company through a transition period during which the Company will be seeking a permanent Chief Executive Officer (“CEO”) and to terminate any prior agreements for employment that may have been in place with Employee.
C. In addition to the capitalized terms defined elsewhere in this Agreement, capitalized terms used herein shall have the definitions ascribed thereto in Section 14.
AGREEMENT
In consideration of the mutual covenants of the parties hereto as hereinafter set forth and other good and valuable consideration, the receipt and sufficiency of which hereby are acknowledged, the parties hereto hereby agree as follows:
1. Employment. The Company shall employ Employee, and Employee hereby agrees to be employed by the Company, upon the terms and conditions set forth in this Agreement, for the period beginning on the Effective Date and ending four (4) years from the date of this Agreement (the “Employment Period”), subject to earlier termination as provided herein.
2. | Position and Duties. |
(a) Position. Employee shall serve as the Chief Executive Officer of the Company for 90 days and thereafter as the Chief Revenue Officer of the Company. Upon termination of employment hereunder for any or no reason, Employee will resign from each such position or office and will sign such documentation as reasonably necessary to effectuate such resignation.
(b) Duties. During the Employment Period, Employee shall devote all of Employee’s business time and attention (except for permitted vacation periods and periods of illness or incapacity) and Employee’s good faith efforts to the business and affairs of the Company Group to achieve the following principal goals: (i) assist in finding a successor Chief Executive Officer (“CEO”); (ii) assist in finding a successor for the current COO; (iii) transition key relationships to the successor CEO; (iv) provide input on the value of future Company acquisitions consistent with BioNovelus’ acquisition strategy; (v) identify potential acquisition targets that may become known through networking or other events; and (vi) confer with BioNovelus’ President & CEO on the West Point Cyber Center of Excellence. During the Employment Period, Employee will (i) perform Employee’s duties faithfully and to the best of Employee’s abilities and (ii) comply with all of the policies of the Company, including, without limitation, such policies with respect to legal compliance, conflicts of interest, confidentiality, code of conduct and business ethics as are from time to time in effect (as the same may be amended or modified from time to time by the Board in its discretion). Employee hereby agrees that, during the Employment Period, Employee’s services will be rendered exclusively to the Company, and Employee may not directly or indirectly render services to, or otherwise act in a business or professional capacity on behalf of or for the benefit of, any other Person, whether or not compensated, except as may otherwise be explicitly permitted by the Board (or its authorized designee) in writing, provided, however, that Employee may serve on the board of one or more for-profit or not-for-profit entities if such service does not conflict with the business interests of BioNovelus.
(c) Board of Directors. Employee shall be appointed to the BioNovelus Board of Directors within ten (10) days following the date of this Agreement.
3. Termination. The Employment Period (a) shall automatically terminate upon (i) Employee’s death, (ii) upon Employee’s Disability or (iii) the consummation of a Sale of the Company, (b) may be terminated by the Company at any time for any reason or no reason (whether for Cause or without Cause) by giving Employee written notice of such termination and (c) may be terminated by Employee at any time by giving the Company’s written notice of such termination at least fifty (50) days in advance of the Termination Date, unless such notice is waived in writing by the Company (in which case such termination shall be effective as of the date set forth in such waiver or such other date designated by the Company). The date that the Employment Period expires or is terminated for any reason (including by virtue of delivery of an Expiration Notice) is referred to herein as the “Termination Date”.
4. | Base Salary and Benefits. |
(a) Base Salary. During the Employment Period, Employee’s base salary shall be $275,000 per year (the “Base Salary”). The Base Salary may be increased but not decreased in the sole discretion of the Board. The Base Salary shall be payable in regular installments in accordance with the Company’s general payroll practices.
(b) Expenses. During the Employment Period, the Company will reimburse Employee for all reasonable travel and other expenses incurred by Employee in connection with the performance of Employee’s duties and obligations under this Agreement. Employee shall comply with such limitations and reporting requirements with respect to expenses as may be established by the Company from time to time for its senior executives generally. With respect to any such reimbursements that are taxable to Employee, such reimbursements shall (i) be paid in accordance with the Company’s normal reimbursement procedures as in effect from time to time, but in no event later than the last day of the taxable year following the taxable year in which the expense giving rise to such reimbursement was incurred, (ii) for any taxable year, not affect the expenses eligible for reimbursement in a different taxable year and (iii) not be subject to liquidation or exchange for other benefits.
2 |
(c) Other Benefits. During the Employment Period, Employee will be entitled to participate in all employee benefit plans or programs (other than any management incentive plan of the Company pursuant to which equity securities may be issued to officers, managers, directors and employees of, and consultants to, any member of the Company) and receive all benefits and perquisites for which salaried employees of the Company generally are eligible under any plan or program now existing or later established by the Company (other than any equity incentive plan or severance arrangement) on a substantially similar basis as other senior executives of the Company and subject to the terms and conditions set forth in such plans and programs as in effect from time to time. Nothing in this Agreement will preclude the Company from amending or terminating any of the plans or programs applicable to salaried employees or senior executives as long as such amendment or termination is applicable to all salaried employees or all senior executives, as the case may be.
(d) Taxes. All compensation payable to Employee hereunder shall be subject to all applicable withholding taxes, normal payroll withholding and any other amounts, if required by law to be withheld.
5. | Severance. |
(a) Termination without Cause or for Good Reason. Subject to the terms and conditions of this Section 5, if the Employment Period is terminated by the Company without Cause or by Employee for Good Reason at any time, Employee shall be entitled to receive her full four (4) years of her Base Salary minus any payments made previously (e.g. if terminated without cause 18 months into her service, she receives 30 months severance, not 48 months) (the “Severance Payments”), and, except as set forth in this Section 5(a) or in Section 5(c), the Company’s obligation to make any other payments or provide any other benefits under this Agreement shall cease as of the Termination Date. When used herein, the “Severance Period” means the earlier of (x) the period ending on the twelve (12)-month anniversary of the Termination Date and (y) the date on which the Employment Period would have expired had the Employment Period not been terminated earlier by the Company without Cause or by Employee for Good Reason. Employee shall forfeit the compensation and other benefits otherwise payable to Employee pursuant to this Section 5(a) unless, prior to the date on which the first payment would otherwise be payable pursuant to this Section 5(a) (and in any event within sixty (60) days after receipt of such Separation Document (as hereinafter defined)), Employee executes and delivers to the Company (and does not revoke or breach), a complete mutual release (i) by Employee in favor of each member of the Company Group and their affiliates, and their respective equity holders, officers, managers, directors, employees, lenders, principals and attorneys, and (ii) by the Company in favor of Employee and her successors and assigns in a form reasonably acceptable to both the Company and Employee.in favor of each member of the Company Group and their affiliates, and their respective equity holders, officers, managers, directors, employees, lenders, principals and attorneys, in a form reasonably acceptable to the Company (the “Separation Document”); provided, however, that if the sixty (60)-day period (together with any applicable consideration and revocation periods) begins in one (1) calendar year and ends in a second calendar year, then regardless of the date on which the Separation Document is actually executed, the Severance Payments (if owed) will be paid in such second calendar year no later than ten (10) days after the last day of such sixty (60)-day period (or, if later, upon the expiration of the applicable consideration and revocation periods), subject to the Company’s ability to accelerate such payments to the extent it would not result in a violation of Code Section 409A. If Employee breaches or revokes the Separation Document provided pursuant to the previous sentence, then Employee shall promptly repay to the Company all amounts paid to Employee pursuant to this Section 5(a) prior to such revocation. If Employee is terminated without Cause or Employee terminates her employment for Good Reason, the Severance Payments shall be made in one lump sum ninety (90) days following the date of termination.
3 |
(b) Other Termination. If the Employment Period is terminated (i) as a result of the death of Employee pursuant to Section 3(a)(i), (ii) upon the Sale of the Company pursuant to Section 3(a)(iii) or (iii) by the Company for Cause or by Employee (other than for Good Reason), except as set forth in Section 5(c), the Company’s obligation to make any other payments or provide any other benefits to Employee under this Agreement shall cease as of the Termination Date. If the Employment Period is terminated by the Company after a determination of a Disability pursuant to Section 3(a)(ii), the Company shall be obligated to pay Employee’s salary and benefits for an additional six (6) months following the date of termination.
(c) Other Benefits. Except (i) as required by law, (ii) as specifically provided in this Section 5, (iii) for the payment of earned but unpaid Base Salary, (iv) for the reimbursement of unreimbursed business expenses pursuant to Section 4(c), and (v) for the payment of earned but unpaid bonus for any fiscal year ended prior to the Termination Date, the Company’s obligation to make any payments or provide any other benefits hereunder shall terminate automatically as of the Termination Date. All of Employee’s rights to fringe benefits and bonuses hereunder (if any) which would accrue or become payable after the termination of the Employment Period shall cease upon such termination.
(d) Termination of Severance. Without limiting the foregoing remedies, if Employee commits a breach of any of the provisions of Sections 6 through 10, the Company shall no longer be obligated to make any payments pursuant to this Section 5, and Employee shall promptly repay any of such payments made pursuant to this Section 5.
(e) Offset. At the time any amount would otherwise become due to Employee pursuant to this Section 5, the Company may, to the extent permitted by applicable law, offset any amounts Employee owes to any member of the Company Group pursuant to any written agreement, note or other instrument relating to indebtedness for borrowed money to which Employee is a party or pursuant to any other liability or obligation by which Employee is bound against any amounts the Company owes Employee hereunder. Any amounts owed to Employee hereunder that constitute “non-qualified deferred compensation” (within the meaning of Code Section 409A(d)(1)) shall, to the extent permitted by applicable law, be subject to the offset in this Section 5(f) only if such offset is not taken until the payment from which such offset is to be taken would otherwise be due to Employee pursuant to this Agreement.
(f) Reversal of Determination. If matters constituting Cause become known to the Company within fifty (50) days after the Termination Date, then the Company may, by delivery of written notice to Employee, treat such termination as being with Cause, and Employee shall promptly, but in any event within five (5) business days following delivery of such notice, return all amounts received by Employee pursuant to this Agreement that Employee would not have been entitled to receive had the Employment Period been terminated by the Company for Cause as of the Termination Date.
4 |
(g) Section 409A. The Company and Employee intend for the Severance Payments set forth in this Section 5 to comply with all applicable provisions of Section 409A of the Code. The Company and Employee agree to construe and interpret this Agreement such that the Severance Payments will be in compliance with Code Section 409A, to the extent permitted by law.
(h) Six-Month Delay. It is intended that the Severance Payments shall be exempt from Code Section 409A as “separation pay due to involuntary separation from service” (within the meaning of Treasury Regulation Section 1.409A-1(b)(9)(iii) or any other applicable exemption under Code Section 409A). However, if it is determined that (i) Employee is a “specified employee,” as defined in Code Section 409A(a)(2)(B)(i), and (ii) such payments constitute a distribution of deferred compensation (within the meaning of Treasury Regulation Section 1.409A-1(b)) upon “separation from service” (within the meaning of Treasury Regulation Section 1.409A-1(h)), after taking into account all available exemptions, then notwithstanding the timing of payment provided in any other Section of this Agreement, no payment, distribution or benefit under this Agreement that constitutes a distribution of deferred compensation on account of such separation from service and that would otherwise be payable during the six (6) month period after such separation from service will be made during such six (6) month period, and any such payment, distribution or benefit will instead be paid on the first business day after such six (6) month period ends.
6. Confidential Information. Employee acknowledges that the information, observations and data obtained by Employee while associated with any member of the Company Group (including, without limitation, trade secrets, know-how, research plans, business, accounting, distribution and sales methods and systems, sales and profit figures and margins and other technical or business information, business, marketing and sales plans and strategies, cost and pricing structures, and information concerning acquisition opportunities and targets in or reasonably related to any member of the Company Group’s business or industry) including, in each case, such information, observations and data obtained prior to the date of this Agreement concerning the business or affairs of any member of the Company Group and its affiliates (collectively, “Confidential Information”) are the property of such entity and agrees that such entity has a protectable interest in such Confidential Information. Therefore, Employee agrees that Employee shall not (during the Employment Period or at any time thereafter) disclose to any unauthorized person or use any such Confidential Information without the prior written consent of the Board unless and to the extent that the aforementioned matters: (a) become or are generally known to and available for use by the industry other than as a result of Employee’s acts or omissions in breach of this Agreement, (b) are required to be disclosed by judicial process or law (provided that Employee shall give prompt advance written notice of such requirement to the Company to enable the Company to seek an appropriate protective order or confidential treatment) or (c) are in furtherance of Employee’s duties under Section 2(b). Employee shall deliver to the Company at the termination of the Employment Period, or at any other time the Company may request, all memoranda, notes, plans, records, reports, computer tapes, printouts and software and other documents and data (and copies thereof) which constitute Confidential Information or Work Product which Employee may then possess or have under Employee’s control. Employee understands and acknowledges that nothing in this Agreement prohibits or limits Employee or Employee’s counsel from initiating communications directly with, responding to any inquiry from, volunteering information to, or providing testimony before, the Securities and Exchange Commission, the Department of Justice, the Financial Industry Regulatory Authority, any other self-regulatory organization or any other governmental, law enforcement, or regulatory authority, regarding this Agreement and its underlying facts and circumstances, or any reporting of, investigation into, or proceeding regarding suspected violations of law, and that Employee is not required to advise or seek permission from the Company before engaging in any such activity. Employee recognizes that, in connection with any such activity, Employee must inform such authority that the information Employee is providing is confidential. The Company does not waive any applicable privileges or the right to continue to protect its privileged attorney-client information, attorney work product, and other privileged information.
5 |
7. Inventions and Patents. Employee hereby assigns to the Company all right, title and interest to all patents and patent applications, all inventions, innovations, improvements, developments, methods, designs, recipes, formulas, analyses, drawings, reports and all similar or related information (in each case whether or not patentable), all copyrights and copyrightable works, all trade secrets, confidential information and know-how, and all other intellectual property rights that both (a) are or were conceived, reduced to practice, developed or made by Employee while engaged by, employed by, or associated with, any member of the Company Group and (b) either that (i) relate to the actual or anticipated business, research and development or existing or future products or services of any member of the Company Group, or (ii) are or were conceived, reduced to practice, developed or made using any of the equipment, supplies, facilities, assets or resources of any member of the Company Group (including, without limitation, any intellectual property rights) (“Work Product”), to the extent allowable under applicable law. Employee shall promptly disclose such Work Product to the Board and perform, at the Company’s expense, all actions reasonably requested by the Board (whether during or after the Employment Period) to establish and confirm the Company’s ownership thereof (including, without limitation, assignments, consents, powers of attorney, applications and other instruments).
8. Non-Competition. In further consideration of the compensation to be paid to Employee hereunder and the consideration paid to Employee for selling the Company to BioNovelus, Employee acknowledges that in the course of Employee’s employment with the Company, Employee is and will become familiar with trade secrets and other Confidential Information concerning the Company Group and that Employee’s services will be of special, unique and extraordinary value to the Company Group. Therefore, Employee hereby covenants and agrees that, during the Employment Period and for the greater of (i) 12 months after the date on which Employee is no longer collecting salary or severance from the Company or Company Group or (ii) until November 21, 2023 (the “Restricted Period”), Employee shall not, without prior express written approval by the Board, or if Employee is terminated prior to the end of the Employment Periodand the BioNovelus CEO determines that Employee is not providing services for a Competing Business (defined below), such permission not to be unreasonably withheld:
6 |
directly or indirectly through any other Person or Persons (whether for compensation or otherwise):
(a) own or hold any debt or equity interest in, manage, operate, control, consult with, render services for, or engage, join or participate in the ownership, management, operation or control of, or furnish any capital or loans to, any Person engaged in or actively pursuing the Business (a “Competing Business”), either as an owner, officer, general or limited partner, principal, proprietor, joint venturer, shareholder, director, member, manager, investor, lender, agent, employee, consultant, trustee, affiliate or otherwise; or
(b) provide to any Competing Business (whether as owner, officer, general or limited partner, principal, proprietor, joint venturer, shareholder, director, member, manager, investor, agent, employee, consultant, trustee, affiliate or otherwise) any executive, managerial, strategic or business development services similar to those services that Employee provided to any member of the Company Group during Employee’s employment with the Company.
Employee acknowledges and agrees that the provisions in this Section 8 shall operate throughout the United States, Canada, and any NATO country in which the Company conducts at least 5% of its business in terms of gross revenues at the time Employee’s employment under the terms of this Agreement is terminated. Nothing herein shall prohibit Employee from being a passive owner of not more than one percent (1%) of the outstanding securities of any publicly traded company engaged in a Competing Business, so long as Employee has no active participation in such Competing Business. In addition, Employee agrees and acknowledges that the potential harm to any member of the Company Group of its non-enforcement outweighs any harm to Employee of its enforcement by injunction or otherwise. Employee acknowledges that Employee has carefully read this Agreement and has given careful consideration to the restraints imposed upon Employee by this Agreement, and is in full accord as to their necessity. Employee expressly acknowledges and agrees that each and every restraint imposed by this Agreement is reasonable with respect to the subject matter, time period and geographical area and that this Section 8 is ancillary to the sale of the Company from the Buckhout Charitable Remainder Trust to BioNovelus.
9. Non-Interference. Employee agrees that, during the Restricted Period, Employee will not, directly or indirectly:
(a) solicit (or participate as an employee, agent, consultant, owner, lender, securityholder, director, manager, partner, member or in any other individual or representative capacity in any business which solicits) business from any Person that is or was a customer, client, distributor, supplier or vendor of any member of the Company Group during the two (2)-year period preceding the date of such solicitation, or from any successor in interest to any such Person, in each case, for the purpose of securing business or contracts related to the Business or any portion thereof; or
7 |
(b) employ, engage or recruit, solicit, contact or approach for employment or engagement (or participate as an employee, agent, consultant, owner, lender, securityholder, director, manager, partner, member or in any other individual or representative capacity in any business that employs, engages or recruits, solicits, contacts or approaches for employment or engagement) any Person that served as an employee, independent contractor or consultant of any member of the Company Group within the two (2) years immediately preceding such action, or otherwise seek or attempt to influence or alter any such Person’s relationship with any member of the Company Group, provided, however, that .Employee shall not be prohibited from employing or engaging any employee who, after being separated from the Company for at least 90 days, initiates contact with Employee without any actions, directly or indirectly, by Employee to prompt such contact. In any litigation regarding such issue, Employee shall bear the burden of proof that such contact was indeed initiated by such employee and shall be required to provide phone, email, and text records to prove such initial contact.
10. Non-disparagement. During the Employment Period or at any time thereafter, neither the Company nor Employee shall directly or indirectly: (i) make any oral or written statement (including via the internet or social media) that disparages or places any member of the Company Group (including any of its past or present officers, employees, products or services) or Employee in a false or negative light or otherwise induce or attempt to induce any Person to cease doing business with any member of the Company Group or Employee, reduce its business or not increase its business with any member of the Company Group or Employee, not grant new business to any member of the Company Group or Employee, or in any way interfere with the relationship between such Person and any member of the Company Group, or (ii) encourage or assist any Person who may or who has filed a lawsuit, charge, claim or complaint against any member of the Company Group or Employee; provided, however, that nothing herein shall prevent the Company Group or Employee from responding to a lawful subpoena or complying with any other legal obligation, in each case, to the extent required by law. If the Company or Employee receives any subpoena or becomes subject to any legal obligation that implicates this Section 10, the Company or Employee will provide prompt written notice of that fact to the relevant members of the Company Group (as set forth in Section 15) or Employee and enclose a copy of the subpoena and any other documents describing the legal obligation. Section 10(i) shall not apply to communications between Employee and her immediate family so long as Employee’s immediate family keeps such communications strictly confidential.
11. Enforcement. If, at the time of enforcement of any of Sections 6 through 10, a court or an arbitrator holds that the duration, scope or area restrictions stated therein are unreasonable under the circumstances then-existing, the parties hereto agree that the maximum duration, scope or area reasonable under such circumstances shall be substituted for the stated duration, scope or area and that the court or arbitrator shall be allowed to revise the restrictions contained herein to cover the maximum period, scope and area permitted by law. Because Employee’s services are unique and because Employee has access to Confidential Information and Work Product, the parties hereto agree that money damages would not be an adequate remedy for any breach of this Agreement. Therefore, in the event of a breach or threatened breach of this Agreement, the Company or its successors or assigns may, in addition to other rights and remedies existing in their favor, apply to any court of competent jurisdiction for and obtain specific performance and/or injunctive or other relief in order to enforce or prevent any violations of the provisions hereof (without (i) the posting of any bond or other security, (ii) the necessity of showing actual damages and (iii) the necessity of showing that monetary damages are an inadequate remedy). Employee agrees that the restrictions contained in Sections 6 through 10 are reasonable.
8 |
12. Employee’s Representations. Employee hereby represents and warrants to the Company that (i) the execution, delivery and performance of this Agreement by Employee and the execution of the Company’s business plan by Employee do not and shall not conflict with, breach, violate or cause a default under any contract, agreement, instrument, order, judgment or decree to which Employee is a party or by which Employee is bound, (ii) Employee is not a party to or bound by any employment agreement, noncompete agreement, nonsolicitation agreement or confidentiality agreement with any other person or entity, (iii) Employee shall not use any confidential information or trade secrets of any third party in connection with the performance of Employee’s duties hereunder and (iv) this Agreement constitutes the valid and binding obligation of Employee, enforceable against Employee in accordance with its terms. Employee hereby acknowledges and represents that Employee has consulted with independent legal counsel regarding Employee’s rights and obligations under this Agreement and that Employee fully understands the terms and conditions contained herein.
13. Survival. Sections 5 through 12 shall survive and continue in full force in accordance with their terms notwithstanding any termination of the Employment Period.
14. | Definitions. |
“Board” means the Board of Managers of Corvus Consulting, LLC.
“Business” means (i) the business of providing for the Department of Defense cybersecurity staffing , (ii) any other material business conducted by any member of the Company Group at any time during the Employment Period or (iii) any business that any member of the Company Group has entered into a letter of intent or agreement at any time during the Employment Period to commence or acquire.
“Cause” shall include the following:
(a) a willful or grossly negligent material breach of fiduciary duty or material breach of the terms of this Agreement or any other agreement between Consultant and the Company (including without limitation any agreements regarding confidentiality, inventions assignment and non-competition), which, in the case of a material breach of the terms of this Agreement or any other agreement, remains uncured for a period of thirty (30) days following receipt of written notice from the Board specifying the nature of such breach;
(b) the commission by Consultant of any act of embezzlement, fraud, larceny or theft on or from the Company;
(c) substantial and continuing gross neglect or inattention by Consultant of its duties under this Agreement or the willful misconduct or gross negligence of Consultant in connection with the performance of such duties which remains uncured for a period of thirty (30) days following receipt of written notice from the Board specifying the nature of such breach; and
(d) the commission by and indictment of Consultant of any crime involving moral turpitude or a felony.
9 |
“CEO” means the Chief Executive Officer of the Company Group.
“Code” means the Internal Revenue Code of 1986, as amended.
“Company Group” means BioNovelus, the Company, and any of their respective Subsidiaries, affiliates, or parent companies as set forth in the public filings of BioNovelus.
“Disability” means Employee’s inability to fulfill Employee’s duties under this Agreement for sixty (60) consecutive days or ninety (90) days in any one hundred eighty (180)-day period due to a mental or physical illness, as determined by a physician selected through the mutual decision of a representative of the Company and a doctor selected by Employee.
“Good Reason” means:
(a) The relocation of Employee’s principal office more than seventy-five (75) miles from the Washington, DC metropolitan area, unless such new office is within 50 miles from Employee’s then-permanent residence;
(b) A material breach of this Agreement by the Company; or
(c) A requirement by the Company that Executive perform any act or refrain from performing any act that would be in violation of any applicable law.
Employee may terminate her employment for Good Reason only by giving the Board prior written notice of termination for Good Reason within 30 days after Employee first becomes aware of the event or condition first giving rise to such Good Reason, and such notice shall become effective thirty (30) days after the date of the notice, unless the Company cures the circumstances that constitute Good Reason within thirty (30) days following the date of the notice, in which case the notice will be of no further effect.
“Corvus” means Corvus Consulting LLC, a Virginia based limited liability company.
“LLC Agreement” means that certain Limited Liability Company Agreement of Corvus.
“Person” means any individual, sole proprietorship, general partnership, limited partnership, limited liability company, joint venture, trust, unincorporated association, corporation, entity or government (whether federal, state, county, city or otherwise, including, without limitation, any instrumentality, division, agency or department thereof).
10 |
“Subsidiary” means, with respect to any Person, any corporation, limited liability company, partnership, association or business entity of which (i) if a corporation, a majority of the total voting power of shares of stock entitled (without regard to the occurrence of any contingency) to vote in the election of directors, managers, or trustees thereof is at the time owned or controlled, directly or indirectly, by that Person or one or more of the other Subsidiaries of that Person or a combination thereof, or (ii) if a limited liability company, partnership, association, or other business entity (other than a corporation), a majority of partnership or other similar ownership interest thereof is at the time owned or controlled, directly or indirectly, by that Person or one or more Subsidiaries of that Person or a combination thereof. For purposes hereof, a Person or Persons shall be deemed to have a majority ownership interest in a limited liability company, partnership, association or other business entity (other than a corporation) if such Person or Persons shall be allocated a majority of limited liability company, partnership, association, or other business entity gains or losses or shall be or control any manager, managing director or general partner of such limited liability company, partnership, association or other business entity. Notwithstanding the foregoing, for purposes hereof, any Person which is consolidated with the Company in its financial statements prepared in accordance with U.S. generally accepted accounting principles, consistently applied, shall be deemed to be a Subsidiary of the Company and any indirect subsidiary of a Person shall be deemed to be a Subsidiary of such Person. For purposes hereof, references to a “Subsidiary” of any Person shall be given effect only at such times that such Person has one or more Subsidiaries.
15. Notices. Any notice provided for in this Agreement must be in writing and must be either (a) personally delivered, (b) delivered by a recognized overnight courier service (charges prepaid) or (c) by email, with receipt acknowledged, to the recipient at the address below indicated:
If to the Company:
Corvus Consulting, LLC
9812 Falls Road, #114-299
Potomac, MD 20854
Email:
If to Employee:
Laurie Buckhout
See signature page hereto
With a copy to:
Culhane Meadows PLLC
1101 Pennsylvania Avenue, N.W.
Suite 300
Washington, D.C. 20004
Attn: Ernest Stern, Esq.
Email: estern@cm.law
or such other address or to the attention of such other person as the recipient party shall have specified by prior written notice to the sending party. Date of service of such notice shall be (x) the date such notice is personally delivered, (y) one (1) business day after date of delivery to the overnight courier if sent by overnight courier or (z) the date such notice is delivered by email, receipt confirmed by recipient.
11 |
16. | General Provisions. |
(a) Severability. Except as provided in Section 11, whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be illegal, invalid or unenforceable in any respect under any present or future law, and if the rights or obligations of any party hereto under this Agreement will not be materially and adversely affected thereby, (i) such provision will be fully severable, (ii) this Agreement will be construed and enforced as if such illegal, invalid or unenforceable provision had never comprised a part hereof, (iii) the remaining provisions of this Agreement will remain in full force and effect and will not be affected by the illegal, invalid or unenforceable provision or by its severance herefrom and (iv) in lieu of such illegal, invalid or unenforceable provision, there will be added automatically as a part of this Agreement a legal, valid and enforceable provision as similar in terms to such illegal, invalid or unenforceable provision as may be possible.
(b) Complete Agreement. This Agreement and those documents expressly referred to herein embody the complete agreement and understanding among the parties hereto and supersede and preempt any prior understandings, agreements or representations by or among the parties, written or oral, which may have been related to the subject matter hereof in any way.
(c) Counterparts; Electronic Transmission. This Agreement may be executed in separate counterparts, each of which is deemed to be an original and all of which taken together constitute one and the same agreement. Delivery of executed signature pages hereof by electronic transmission (including a facsimile or .pdf file) shall constitute effective and binding execution and delivery of this Agreement.
(d) Amendment and Waiver. The provisions of this Agreement may be amended and waived only with the prior written consent of each of the Company and Employee.
(e) Business Days. If any time period for giving notice or taking action hereunder expires on a day which is a Saturday, Sunday or legal holiday in the state in which the Company’s chief executive office is located, the time period shall be automatically extended to the business day immediately following such Saturday, Sunday or holiday.
(f) No Strict Construction. The language used in this Agreement shall be deemed to be the language chosen by the parties hereto to express their mutual intent, and no rule of strict construction shall be applied against any party.
(g) Assignment. Except as otherwise provided herein, this Agreement shall bind and inure to the benefit of and be enforceable by Employee, the Company and their respective successors and assigns; provided, however, that the rights and obligations of Employee under this Agreement shall not be assignable other than to (a) any affiliate of the Company Group or (b) any purchaser of all or substantially all of the assets of any member of the Company Group.
12 |
(h) Governing Law. This Agreement shall be construed in accordance with the internal laws, but not the law of conflicts, of the Commonwealth of Virginia. For the purposes of any suit, action, or other proceeding arising out of this Agreement or with respect to Employee’s employment hereunder that is not otherwise subject to arbitration, the parties: (i) agree to submit to the exclusive jurisdiction of the federal or state courts or agencies located in Chicago, Illinois; (ii) waive any objection to personal jurisdiction or venue in such jurisdiction, and agree not to plead or claim forum non conveniens; and (iii) waive their respective rights to a jury trial of any claims and causes of action, and agree to have any matter heard and decided solely by the court.
(i) WAIVER OF JURY TRIAL. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY OF ANY CLAIM OR CAUSE OF ACTION IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS OR EVENTS CONTEMPLATED HEREBY OR ANY COURSE OF CONDUCT, COURSE OF DEALING, STATEMENTS (WHETHER VERBAL OR WRITTEN) OR ACTIONS OF ANY PARTY HERETO. THE PARTIES HERETO EACH AGREE THAT ANY AND ALL SUCH CLAIMS AND CAUSES OF ACTION SHALL BE TRIED BY THE COURT WITHOUT A JURY. EACH OF THE PARTIES HERETO FURTHER WAIVES ANY RIGHT TO SEEK TO CONSOLIDATE ANY SUCH LEGAL PROCEEDING IN WHICH A JURY TRIAL HAS BEEN WAIVED WITH ANY OTHER LEGAL PROCEEDING IN WHICH A JURY TRIAL CANNOT OR HAS NOT BEEN WAIVED.
(j) Arbitration. Except as expressly provided otherwise in this Agreement, in the event of any controversy between the parties hereto arising out of, or relating to, this Agreement, including, without limitation, any controversy concerning the negotiation, validity or enforceability of this Agreement and any dispute as to whether a particular controversy is subject to arbitration, which cannot be settled amicably by the parties hereto, such controversy or dispute shall be finally, exclusively and conclusively settled by mandatory arbitration conducted expeditiously in accordance with the JAMS Comprehensive Arbitration Rules, by a panel of three (3) arbitrators; provided that, notwithstanding the foregoing, each of the parties hereto shall be entitled to seek a temporary restraining order and any other emergency injunctive relief, from a court of competent jurisdiction, restraining the other party from committing or continuing any violation of the provisions hereof until such time as the controversy is adjudicated in arbitration; provided further, that monetary damages for any breach of this Agreement shall be determined pursuant to this subsection. If the parties hereto are unable to agree on the selection of an arbitration panel, then the arbitration panel shall be appointed by JAMS according to its rules on arbitrator selection, which appointment shall be made within ten (10) days of JAMS’ receipt of notice from a party that the parties are unable to agree on an arbitration panel. Any party hereto may institute such arbitration proceeding by filing the required documents with the arbitration service and giving written notice to the other party hereto. A hearing shall be held by the arbitrator at JAMS’ facilities located in Washington, DC within thirty (30) days of the arbitration panel’s appointment. The decision of the arbitrators shall be final and binding upon all parties and shall be rendered pursuant to a written decision which contains a detailed recital of the arbitrators’ reasoning. Judgment upon the award rendered may be entered in any court having jurisdiction thereof pursuant to the Federal Arbitration Act, 9 U.S.C. Sec. 1, et seq.
13 |
(k) Information Requests. At any time during the Restricted Period, any member of the Company Group may request that Employee supply such information as it deems reasonably necessary to ascertain whether Employee has complied with, or has violated any provision of Sections 6 through 10. Any such request for information will be delivered in accordance with Section 15. Employee shall furnish the requested information to the applicable member of the Company Group within a reasonable time, but not later than twenty (20) business days, following the receipt of such request.
(l) Section 409A. Notwithstanding anything herein to the contrary, this Agreement is intended to be interpreted and applied so that the payment of the benefits set forth herein either (i) shall be exempt from the requirements of Section 409A of the Code, or shall comply with the requirements of such provision. Notwithstanding anything in this Agreement or elsewhere to the contrary, distributions upon termination of Employee’s employment may only be made upon a “separation from service” as determined under Section 409A of the Code. Each payment under this Agreement or otherwise shall be treated as a separate payment for purposes of Section 409A of the Code. In no event may Employee, directly or indirectly, designate the calendar year of any payment to be made under this Agreement or otherwise that constitutes a “deferral of compensation” within the meaning of Section 409A of the Code. Notwithstanding any of the foregoing to the contrary, the Company Group and its respective officers, directors, employees, or agents make no guarantee that the terms of this Agreement as written comply with, or are exempt from, the provisions of Code Section 409A, and none of the foregoing shall have any liability for the failure of the terms of this Agreement as written to comply with, or be exempt from, the provisions of Code Section 409A.
[Signature Page Follows]
14 |
IN WITNESS WHEREOF, the parties hereto have executed this Employment Agreement as of the date first written above.
COMPANY: | |||
CORVUS CONSULTING, LLC | |||
By: | ![]() |
||
Name: Mark C. Fuller | |||
Title: President and CEO | |||
EMPLOYEE: | |||
![]() |
|||
Laurie Buckhout | |||
Address: 15416 Kentwell Circle | |||
Centreville, VA 20120 | |||
Email: laurie.buckhout @gmail.com |
Exhibit 31.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO RULES 13a-14(a) AND 15d-14(a)
OF THE SECURITIES EXCHANGE ACT OF 1934
I, Mark C. Fuller, Chief Executive Officer of Castellum. Inc. (the “Company”), certify that:
(1) I have reviewed this Quarterly Report on Form 10-Q for the fiscal period ended September 30, 2022;
(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
(3) Based on my knowledge, the financial statements, and other financial information included in the report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods represented in this report;
(4) The Company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:
(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which the report is being prepared;
(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the Company’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting; and
(5) The Company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and to the audit committee of the board of directors (or persons fulfilling the equivalent function):
(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and
(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.
November 14, 2022
/s/ Mark C. Fuller | |
Mark C. Fuller | |
Chief Executive Officer | |
(Principal Executive Officer) |
Exhibit 31.2
CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO RULES 13a-14(a) AND 15d-14(a)
OF THE SECURITIES EXCHANGE ACT OF 1934
I, David T. Bell, Chief Financial Officer of Castellum, Inc. (the “Company”), certify that:
(1) I have reviewed this Quarterly Report on Form 10-Q for the fiscal period ended September 30, 2022;
(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
(3) Based on my knowledge, the financial statements, and other financial information included in the report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods represented in this report;
(4) The Company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:
(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which the report is being prepared;
(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the Company’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting; and
(5) The Company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and to the audit committee of the board of directors (or persons fulfilling the equivalent function):
(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and
(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.
November 14, 2022
/s/ David T. Bell | |
David T. Bell | |
Chief Financial Officer |
(Principal Financial Officer and Principal Accounting Officer)
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Castellum, Inc. (the “Company”) for the period ended September 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Mark C. Fuller, Chief Executive Officer of the Company hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ Mark C. Fuller | |
Mark C. Fuller | |
Chief Executive Officer | |
(Principal Executive Officer) |
November 14, 2022
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Castellum, Inc. (the “Company”) for the period ended September 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, David T. Bell, Chief Financial Officer of the Company hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ David T. Bell | |
David T. Bell | |
Chief Financial Officer |
(Principal Financial Officer and Principal Accounting Officer)
November 14, 2022